Next Article in Journal
Targeted Delivery of siRNA to Tumor Cells with Designed Ankyrin Repeat Protein Nanocomplexes
Previous Article in Journal
HPLC-ESI-MS/MS Assay for Quantitative Metabolic Profiling in Fermentation Broths from β–Lactam Antibiotics Production
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Sci. Pharm.
Volume 77
Issue 6
10.3797/scipharm.oephg.21.SL-03
scipharm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Abstract

How to Deal with Ion Suppression – the Foe of HPLC-MS/MS

by
C. SEGER
* and
A. GRIESMACHER
Division of Mass Spectrometry and Chromatography, Institute of Medical and Chemical Laboratory Diagnostics (ZIMCL), University Hospital Innsbruck, Austria
*
Author to whom correspondence should be addressed.
Sci. Pharm. 2009, 77(6), 170; https://doi.org/10.3797/scipharm.oephg.21.SL-03
Submission received: 16 April 2009 / Accepted: 16 April 2009 / Published: 16 April 2009
Versions Notes

Abstract

It is well accepted, that a HPLC-MS/MS assay can outperform immunoassays in therapeutic drug monitoring (TDM) due to its increased accuracy, sensitivity, and precision. However, the occurrence of sudden and unpredictable ion yield attenuation, can hamper assay performance. Such “ion suppression effects” are considered a central analytical problem if using an MS/MS detector in bio-analysis. Since pathological patient specimen compositions or individual co-medications may be major causes for ion yield fluctuations, measures have to be taken to evaluate these interferences prior to transferring an HPLC-MS/MS assay to routine use.

Share and Cite

MDPI and ACS Style

SEGER, C.; GRIESMACHER, A. How to Deal with Ion Suppression – the Foe of HPLC-MS/MS. Sci. Pharm. 2009, 77, 170. https://doi.org/10.3797/scipharm.oephg.21.SL-03

AMA Style

SEGER C, GRIESMACHER A. How to Deal with Ion Suppression – the Foe of HPLC-MS/MS. Scientia Pharmaceutica. 2009; 77(Short Lectures (SL)):170. https://doi.org/10.3797/scipharm.oephg.21.SL-03

Chicago/Turabian Style

SEGER, C., and A. GRIESMACHER. 2009. "How to Deal with Ion Suppression – the Foe of HPLC-MS/MS" Scientia Pharmaceutica 77, Short Lectures (SL): 170. https://doi.org/10.3797/scipharm.oephg.21.SL-03

APA Style

SEGER, C., & GRIESMACHER, A. (2009). How to Deal with Ion Suppression – the Foe of HPLC-MS/MS. Scientia Pharmaceutica, 77(Short Lectures (SL)), 170. https://doi.org/10.3797/scipharm.oephg.21.SL-03

Article Metrics

Back to TopTop